Clinical trials: Salmonella Infection
Typhoid Fever
Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants
The purpose of this study is to evaluate the safety, immunogenicity, and compatibility of our Vi-rEPA conjugate administered to infants with their routine vaccinations.
- Trial name
- NCT00342628
- Testing
- Vi-rEPA conjugate vaccine for typhoid fever, Hib-TT, DTP
- Where
- Vietnam
- Volunteers
- 301 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Typhoid, Fever
Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever
Sample size of 360 children with typhoid fever were enrolled and randomly divided in two groups. All the children were enrolled in the trial from Pediatrics emergency. Informed consent was obtained from parents.
- Trial name
- NCT07150065
- Testing
- Levofloxacin, ciprofloxacin
- Where
- Pakistan
- Volunteers
- 360 people
- Sponsor
- Avicenna Medical College Lahore
Typhoid Fever
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).
- Trial name
- NCT05613205
- Testing
- TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine
- Where
- Belgium
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Typhoid Fever
Evaluation Study of DPP® Typhoid Assay
Fever management is a major problem in Low and Middle Income Countries (LMICs) where access to good quality diagnostic test is often unavailable.
- Trial name
- NCT05579821
- Testing
- Typhoid DPP assay
- Where
- Pakistan
- Volunteers
- 387 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Salmonella Infection
NCCLS Interpretive Criteria for Salmonella
To determine the clinical significance of gene mutations encoding antibiotic resistance, but not expressed as clinical resistance, in Salmonella bacteria
- Trial name
- NCT00177658
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Salmonella Typhi Infection
Investigating Typhoid Fever Pathogenesis
Typhoid fever results from infection with a bacterium called Salmonella Typhi and is a major cause of illness worldwide. It is estimated to infect 20-25 million people every year and can affect people of all ages, but is…
- Trial name
- TYGER (NCT03067961)
- Testing
- Salmonella Typhi (S. Typhi)
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid Fever
CVD 909 Vi Prime Boost Study
The purpose of this research study is to see if giving a typhoid vaccine by mouth (an experimental vaccine, CVD 909) before giving a vaccine shot (Typhim Vi) will result in a better immune response than giving Typhim Vi vaccine…
- Trial name
- NCT00326443
- Testing
- CVD 909, Vi Polysaccharide
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Typhoid Fever
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.
- Trial name
- NCT00498654
- Testing
- Ty800 (Salmonella typhi) Oral Vaccine
- Where
- 5 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Avant Immunotherapeutics
Typhoid Fever
Vellore Typhoid Vaccine Impact Trial
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
- Trial name
- VEVACT (NCT05500482)
- Testing
- Typhoid conjugate Vaccine
- Where
- India
- Volunteers
- 72,400 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Undifferentiated Febrile Illness
Nepal Undifferentiated Febrile Illness Trial
The purpose of the study is to determine whether azithromycin or cotrimoxazole is the best empirical treatment for undifferentiated febrile illness in Nepal
- Trial name
- NUFIT (NCT02773407)
- Testing
- Azithromycin, Co-trimoxazole
- Where
- 2 sites in Nepal
- Volunteers
- 330 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in subjects from various age groups in India and Pakistan where Typhoid Fever is highly endemic and an efficacious vaccine…
- Trial name
- NCT01229176
- Testing
- Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine
- Where
- 2 sites in India, Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
The purpose of this study is to evaluate the safety and tolerability of EuTCV, in comparison to TCV (Typbar-TCV™, Bharat Biotech) and Vi-Polysaccharide vaccine (Typhim Vi®, Sanofi Pasteur) in healthy adult volunteers.
- Trial name
- NCT03956524
- Testing
- EuTCV, Typbar-TCV™, Typhim Vi®
- Where
- Philippines
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Typhoid Vaccination, Typhoid
ZyVac-TCV Bangladesh Study
This is a prospective closed cohort, open-label, phase III effectiveness study using a test-negative design of a typhoid conjugate vaccine, ZyVac® TCV (purified Vi capsular polysaccharide of Salmonella Typhi conjugated to tetanus…
- Conditions
- Typhoid Vaccination, Typhoid, Typhoid Fever
- Trial name
- NCT06757283
- Testing
- Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
- Where
- Bangladesh
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Salmonella Typhi Infection
Understanding How Salmonella Typhi Infects Humans (Bottlenecks)
Typhoid fever is an infection caused by the bacteria Salmonella Typhi (S. Typhi). S. Typhi causes disease principally in developing countries where communities do not have access to safe water or adequate sanitation.
- Trial name
- NCT03889067
- Testing
- Salmonella Typhi challenge
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Enteric Fever, Acute Febrile Illness
Transcriptomic Responses for the Identification of Pathogens
Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions.
- Conditions
- Enteric Fever, Acute Febrile Illness, Typhoid, Paratyphoid Fever
- Trial name
- TRiP (NCT04878549)
- Testing
- 5-gene transcription signature
- Where
- India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HIV Infections, HIV Seronegativity
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
The purpose of this study is to evaluate the safety and effectiveness of giving healthy volunteers a new oral HIV vaccine which has been incorporated into a bacterial cell.
- Trial name
- NCT00000868
- Testing
- Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)